Kinase inhibitor drugs:
Saved in:
| Main Author: | |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Hoboken, N.J.
J. Wiley
c2009
|
| Series: | Wiley series in drug discovery and development
|
| Subjects: | |
| Online Access: | TUM01 Volltext |
| Item Description: | Includes bibliographical references and index A comprehensive resource on case studies of marketed kinase drugs and promising drug trials. Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. |
| Physical Description: | 1 Online-Ressource (1 online resource) |
| ISBN: | 0470524952 0470524960 9780470524954 9780470524961 |
Staff View
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV040472741 | ||
| 003 | DE-604 | ||
| 005 | 20130325 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 121011s2009 |||| o||u| ||||||eng d | ||
| 020 | |a 0470524952 |c electronic bk. |9 0-470-52495-2 | ||
| 020 | |a 0470524960 |9 0-470-52496-0 | ||
| 020 | |a 9780470524954 |c electronic bk. |9 978-0-470-52495-4 | ||
| 020 | |a 9780470524961 |9 978-0-470-52496-1 | ||
| 035 | |a (OCoLC)1039295603 | ||
| 035 | |a (DE-599)BVBBV040472741 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-91 | ||
| 100 | 1 | |a Li, Rongshi |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Kinase inhibitor drugs |c Rongshi Li, Jeffrey A. Stafford |
| 264 | 1 | |a Hoboken, N.J. |b J. Wiley |c c2009 | |
| 300 | |a 1 Online-Ressource (1 online resource) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Wiley series in drug discovery and development | |
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a A comprehensive resource on case studies of marketed kinase drugs and promising drug trials. Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. | ||
| 650 | 4 | |a Protein kinases / Inhibitors / Therapeutic use | |
| 650 | 4 | |a Antineoplastic agents | |
| 650 | 4 | |a Neoplasms / drug therapy | |
| 650 | 4 | |a Protein Kinase Inhibitors / therapeutic use | |
| 650 | 4 | |a Antineoplastic Agents / therapeutic use | |
| 650 | 4 | |a Drug Discovery | |
| 650 | 4 | |a Protein Kinase Inhibitors / pharmacology | |
| 650 | 4 | |a Protein Kinases / metabolism | |
| 700 | 1 | |a Stafford, Jeffrey A. |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 0-470-27829-3 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-0-470-27829-1 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-0-470-27829-1 |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=294247 |x Verlag |3 Volltext |
| 912 | |a ZDB-4-NLEBK | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-025320030 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=294247 |l TUM01 |p ZDB-4-NLEBK |q TUM_PDA_EBSCO_MED_gekauft |x Verlag |3 Volltext | |
Record in the Search Index
| _version_ | 1804149536613990400 |
|---|---|
| any_adam_object | |
| author | Li, Rongshi |
| author_facet | Li, Rongshi |
| author_role | aut |
| author_sort | Li, Rongshi |
| author_variant | r l rl |
| building | Verbundindex |
| bvnumber | BV040472741 |
| collection | ZDB-4-NLEBK |
| ctrlnum | (OCoLC)1039295603 (DE-599)BVBBV040472741 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02604nmm a2200505zc 4500</leader><controlfield tag="001">BV040472741</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20130325 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">121011s2009 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0470524952</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-470-52495-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0470524960</subfield><subfield code="9">0-470-52496-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780470524954</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-470-52495-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780470524961</subfield><subfield code="9">978-0-470-52496-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1039295603</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV040472741</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-91</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Li, Rongshi</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Kinase inhibitor drugs</subfield><subfield code="c">Rongshi Li, Jeffrey A. Stafford</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hoboken, N.J.</subfield><subfield code="b">J. Wiley</subfield><subfield code="c">c2009</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (1 online resource)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Wiley series in drug discovery and development</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">A comprehensive resource on case studies of marketed kinase drugs and promising drug trials. Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein kinases / Inhibitors / Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms / drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein Kinase Inhibitors / therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents / therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Discovery</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein Kinase Inhibitors / pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein Kinases / metabolism</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stafford, Jeffrey A.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">0-470-27829-3</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-0-470-27829-1</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-0-470-27829-1</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=294247</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-NLEBK</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-025320030</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=294247</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-4-NLEBK</subfield><subfield code="q">TUM_PDA_EBSCO_MED_gekauft</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV040472741 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T00:24:35Z |
| institution | BVB |
| isbn | 0470524952 0470524960 9780470524954 9780470524961 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-025320030 |
| oclc_num | 1039295603 |
| open_access_boolean | |
| owner | DE-91 DE-BY-TUM |
| owner_facet | DE-91 DE-BY-TUM |
| physical | 1 Online-Ressource (1 online resource) |
| psigel | ZDB-4-NLEBK ZDB-4-NLEBK TUM_PDA_EBSCO_MED_gekauft |
| publishDate | 2009 |
| publishDateSearch | 2009 |
| publishDateSort | 2009 |
| publisher | J. Wiley |
| record_format | marc |
| series2 | Wiley series in drug discovery and development |
| spelling | Li, Rongshi Verfasser aut Kinase inhibitor drugs Rongshi Li, Jeffrey A. Stafford Hoboken, N.J. J. Wiley c2009 1 Online-Ressource (1 online resource) txt rdacontent c rdamedia cr rdacarrier Wiley series in drug discovery and development Includes bibliographical references and index A comprehensive resource on case studies of marketed kinase drugs and promising drug trials. Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Protein kinases / Inhibitors / Therapeutic use Antineoplastic agents Neoplasms / drug therapy Protein Kinase Inhibitors / therapeutic use Antineoplastic Agents / therapeutic use Drug Discovery Protein Kinase Inhibitors / pharmacology Protein Kinases / metabolism Stafford, Jeffrey A. Sonstige oth Erscheint auch als Druck-Ausgabe, Hardcover 0-470-27829-3 Erscheint auch als Druck-Ausgabe, Hardcover 978-0-470-27829-1 http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=294247 Verlag Volltext |
| spellingShingle | Li, Rongshi Kinase inhibitor drugs Protein kinases / Inhibitors / Therapeutic use Antineoplastic agents Neoplasms / drug therapy Protein Kinase Inhibitors / therapeutic use Antineoplastic Agents / therapeutic use Drug Discovery Protein Kinase Inhibitors / pharmacology Protein Kinases / metabolism |
| title | Kinase inhibitor drugs |
| title_auth | Kinase inhibitor drugs |
| title_exact_search | Kinase inhibitor drugs |
| title_full | Kinase inhibitor drugs Rongshi Li, Jeffrey A. Stafford |
| title_fullStr | Kinase inhibitor drugs Rongshi Li, Jeffrey A. Stafford |
| title_full_unstemmed | Kinase inhibitor drugs Rongshi Li, Jeffrey A. Stafford |
| title_short | Kinase inhibitor drugs |
| title_sort | kinase inhibitor drugs |
| topic | Protein kinases / Inhibitors / Therapeutic use Antineoplastic agents Neoplasms / drug therapy Protein Kinase Inhibitors / therapeutic use Antineoplastic Agents / therapeutic use Drug Discovery Protein Kinase Inhibitors / pharmacology Protein Kinases / metabolism |
| topic_facet | Protein kinases / Inhibitors / Therapeutic use Antineoplastic agents Neoplasms / drug therapy Protein Kinase Inhibitors / therapeutic use Antineoplastic Agents / therapeutic use Drug Discovery Protein Kinase Inhibitors / pharmacology Protein Kinases / metabolism |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=294247 |
| work_keys_str_mv | AT lirongshi kinaseinhibitordrugs AT staffordjeffreya kinaseinhibitordrugs |